TRENDING :  Market Movers  |  Top 50   SPY (-0.27%)    BYND (-1.09%)    ARQL (-1.04%)    ARCI (3.34%)    ELTK (-7.88%)    NVAX (8.81%)    CANF (48.55%)    VXX (0.64%)    BPY (-1.26%)    RIOT (4.43%)    QQQ (-1.19%)    PANW (-1.49%)    ORLY (0.59%)    NVDA (-1.98%)    MCHP (-3.51%)    LTCUSD (%)    KSS (-0.74%)    GTN (-1.13%)    GOOG (-1.84%)    GLW (-0.54%)    FTNT (-1.23%)    ETHUSD (%)    DIS (-1.03%)    DB (-1.98%)    CGC (-3.44%)

 BCRX - BioCryst Pharmaceuticals

$7.27 [-0.07][-0.82%]

Next Earnings

8/6/2019

BMO

Recommend
Trade Idea »



ANALYST RATINGS

Quarterly Rating Chart
Rating

2


1=Strong Buy, 2=Buy, 3=Hold, 4=Underperform, 5=Sell
Price Targets
High $18.00
Low $8.00
Average $13.00
Current $7.27

CompanyAnalyst NamePT ActionActionRatingTargetDate
JMP SecuritiesLowersMaintainsStrong Buy$18.0004/02/19
BarclaysGena WangRaisesMaintainsHold$8.0004/02/19
*Last 90 days

OPEN RECOMMENDATIONS

No recommendations found.


This list is limited to recommendations made in last 7 days only. Subscribe to a service to see all their recommendations.

TRADERS TRACKING $BCRX

Service NameTrader% Success
testR. belegger0.00 %Follow

TRENDING ARTICLES



Biocryst Pharmaceuticals Inc (BCRX) Q1 2019 Earnings Call Transcript

05/08/19
Image source The Motley Fool Biocryst Pharmaceuticals Inc NASDAQ BCRX Q1 160 2019 Earnings Call May 8 2019 8 30 a m ET Contents Prepared Remarks Questions and Answers Call Participants Prepared Remarks Operator

BioCryst Pharmaceuticals (BCRX) Reports Q1 Loss, Tops Revenue Estimates

05/08/19
BioCryst Pharmaceuticals BCRX came out with a quarterly loss of 0 28 per share in line with the Zacks Consensus Estimate This compares to loss of 0 26 per share a year ago These figures are adjusted for non recurring items A quarter ago it was expected that this drugmaker would post a

Analysts Estimate BioCryst Pharmaceuticals (BCRX) to Report a Decline in Earnings: What to Look Out for

05/01/19
BioCryst Pharmaceuticals BCRX is expected to deliver a year over year decline in earnings on lower revenues when i t report s results for the quarter ended March 2019 This widely known consensus outlook gives a good sense of the company s earnings picture but how the actual results compare